Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2014 - 2020)
Relmada Therapeutics (RLMD) posted quarterly Long-Term Debt Issuances of $110247.0 for Q1 2020, up 28.24% year-over-year from $85969.0 in Q2 2019, and down 56.59% quarter-over-quarter from $253957.0 in Q4 2019.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2014 - 2020) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Long-Term Debt Issuances for 7 consecutive years, with $110247.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Long-Term Debt Issuances rose 28.24% year-over-year to $110247.0; the TTM figure through Dec 2020 stood at $110247.0 (down 77.25% YoY), while the FY2022 annual figure was $50000.0, changed N/A from the prior year.
- Long-Term Debt Issuances eased to $110247.0 in Q1 2020 per RLMD's latest filing, from $253957.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $4.0 million in Q3 2017 and bottomed at -$6.3 million in Q1 2018.
- Historically, Long-Term Debt Issuances has averaged $91750.5 across 5 years, with a median of $85969.0 in 2019.
- Annual changes were most pronounced in 2017 — Long-Term Debt Issuances jumped 4439.27% — and 2018, when it slumped 7691.16%.
- Relmada Therapeutics' Long-Term Debt Issuances stood at $54403.0 in 2016, then surged by 4439.27% to $2.5 million in 2017, then tumbled by 96.54% to $85466.0 in 2018, then soared by 197.14% to $253957.0 in 2019, then slumped by 56.59% to $110247.0 in 2020.
- Business Quant data shows RLMD's Long-Term Debt Issuances at $110247.0 in Q1 2020, $253957.0 in Q4 2019, and $108279.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 110,247.00 |
| Dec 31, 2019 | 253,957.00 |
| Sep 30, 2019 | 108,279.00 |
| Mar 31, 2019 | 85,969.00 |
| Dec 31, 2018 | 85,466.00 |
| Sep 30, 2018 | 84,966.00 |
| Mar 31, 2018 | 26,700.00 |
| Dec 31, 2017 | 2.47 Mn |
| Sep 30, 2017 | 4.04 Mn |
| Jun 30, 2017 | 27,583.00 |
| Mar 31, 2017 | 82,450.00 |
| Dec 31, 2016 | 54,403.00 |
| Sep 30, 2016 | 109,234.00 |
| Mar 31, 2016 | 88,533.00 |
| Dec 31, 2015 | 87,915.00 |
| Sep 30, 2015 | 87,304.00 |
| Jun 30, 2015 | -1.00 |
| Mar 31, 2015 | 38,089.00 |
| Dec 31, 2014 | 107,096.00 |
| Sep 30, 2014 | 148,441.00 |